DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; « less
Publication Date:
Research Org.:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
INDUSTRY
OSTI Identifier:
1182329
Grant/Contract Number:  
AC02-06CH11357
Resource Type:
Accepted Manuscript
Journal Name:
Proceedings of the National Academy of Sciences of the United States of America
Additional Journal Information:
Journal Volume: 112; Journal Issue: 11; Journal ID: ISSN 0027-8424
Publisher:
National Academy of Sciences, Washington, DC (United States)
Country of Publication:
United States
Language:
ENGLISH
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, and Fantin, Valeria R. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. United States: N. p., 2015. Web. doi:10.1073/pnas.1420785112.
Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, & Fantin, Valeria R. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. United States. https://doi.org/10.1073/pnas.1420785112
Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, and Fantin, Valeria R. Mon . "PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations". United States. https://doi.org/10.1073/pnas.1420785112. https://www.osti.gov/servlets/purl/1182329.
@article{osti_1182329,
title = {PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations},
author = {Zou, Helen Y. and Li, Qiuhua and Engstrom, Lars D. and West, Melissa and Appleman, Vicky and Wong, Katy A. and McTigue, Michele and Deng, Ya-Li and Liu, Wei and Brooun, Alexei and Timofeevski, Sergei and McDonnell, Scott R. P. and Jiang, Ping and Falk, Matthew D. and Lappin, Patrick B. and Affolter, Timothy and Nichols, Tim and Hu, Wenyue and Lam, Justine and Johnson, Ted W. and Smeal, Tod and Charest, Al and Fantin, Valeria R.},
abstractNote = {},
doi = {10.1073/pnas.1420785112},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
number = 11,
volume = 112,
place = {United States},
year = {Mon Mar 02 00:00:00 EST 2015},
month = {Mon Mar 02 00:00:00 EST 2015}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 195 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

The transcriptional landscape and mutational profile of lung adenocarcinoma
journal, September 2012


Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1
journal, July 2014

  • Yamazaki, Shinji; Lam, Justine L.; Zou, Helen Y.
  • Journal of Pharmacology and Experimental Therapeutics, Vol. 351, Issue 1
  • DOI: 10.1124/jpet.114.217141

Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
journal, January 2011


The protein tyrosine kinase family of the human genome
journal, November 2000


A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis
journal, October 2009

  • Woolfenden, Steve; Zhu, Haihao; Charest, Al
  • genesis, Vol. 47, Issue 10
  • DOI: 10.1002/dvg.20545

Acquired Resistance to Crizotinib from a Mutation in CD74ROS1
journal, June 2013

  • Awad, Mark M.; Katayama, Ryohei; McTigue, Michele
  • New England Journal of Medicine, Vol. 368, Issue 25
  • DOI: 10.1056/NEJMoa1215530

Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.
journal, May 2013


Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
journal, November 2013


Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
journal, January 2003

  • Charest, A.; Kheifets, V.; Park, J.
  • Proceedings of the National Academy of Sciences, Vol. 100, Issue 3
  • DOI: 10.1073/pnas.242741799

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
journal, November 2013

  • Davare, M. A.; Saborowski, A.; Eide, C. A.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 48
  • DOI: 10.1073/pnas.1319583110

Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
journal, August 2013

  • Sun, Huiyong; Li, Youyong; Li, Dan
  • Journal of Chemical Information and Modeling, Vol. 53, Issue 9
  • DOI: 10.1021/ci400188q

Acquired resistance to tyrosine kinase inhibitors during cancer therapy
journal, February 2008

  • Engelman, Jeffrey A.; Settleman, Jeffrey
  • Current Opinion in Genetics & Development, Vol. 18, Issue 1
  • DOI: 10.1016/j.gde.2008.01.004

Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
journal, June 2012


Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
journal, November 2001

  • Bhattacharjee, A.; Richards, W. G.; Staunton, J.
  • Proceedings of the National Academy of Sciences, Vol. 98, Issue 24
  • DOI: 10.1073/pnas.191502998

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
journal, May 2012


The landscape of kinase fusions in cancer
journal, September 2014

  • Stransky, Nicolas; Cerami, Ethan; Schalm, Stefanie
  • Nature Communications, Vol. 5, Issue 1
  • DOI: 10.1038/ncomms5846

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
journal, January 2014

  • Wiesner, Thomas; He, Jie; Yelensky, Roman
  • Nature Communications, Vol. 5, Issue 1
  • DOI: 10.1038/ncomms4116

Diversity of Mechanism-Based Pharmacodynamic Models
journal, May 2003

  • Mager, Donald E.; Wyska, Elzbieta; Jusko, William J.
  • Drug Metabolism and Disposition, Vol. 31, Issue 5
  • DOI: 10.1124/dmd.31.5.510

Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.
journal, May 2010


Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer
journal, November 2014

  • Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue
  • New England Journal of Medicine, Vol. 371, Issue 21
  • DOI: 10.1056/NEJMoa1406766

ALK in Lung Cancer: Past, Present, and Future
journal, March 2013


Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
journal, October 2014


Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
journal, June 2013

  • Taipale, Mikko; Krykbaeva, Irina; Whitesell, Luke
  • Nature Biotechnology, Vol. 31, Issue 7
  • DOI: 10.1038/nbt.2620

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
journal, August 2012


ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
journal, April 2012

  • Ou, Sai-Hong Ignatius; Tan, Jackie; Yen, Yun
  • Expert Review of Anticancer Therapy, Vol. 12, Issue 4
  • DOI: 10.1586/era.12.17

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
journal, December 2011


Characterization of ROS1 cDNA from a human glioblastoma cell line.
journal, June 1990

  • Birchmeier, C.; O'Neill, K.; Riggs, M.
  • Proceedings of the National Academy of Sciences, Vol. 87, Issue 12
  • DOI: 10.1073/pnas.87.12.4799

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
journal, February 2015


Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
journal, December 2007


RET, ROS1 and ALK fusions in lung cancer
journal, February 2012

  • Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki
  • Nature Medicine, Vol. 18, Issue 3
  • DOI: 10.1038/nm.2658

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
journal, September 2014


ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
journal, March 2012

  • Bergethon, Kristin; Shaw, Alice T.; Ignatius Ou, Sai-Hong
  • Journal of Clinical Oncology, Vol. 30, Issue 8
  • DOI: 10.1200/JCO.2011.35.6345

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
journal, March 2003

  • Charest, Alain; Lane, Keara; McMahon, Kevin
  • Genes, Chromosomes and Cancer, Vol. 37, Issue 1
  • DOI: 10.1002/gcc.10207

Oncogenic pathway signatures in human cancers as a guide to targeted therapies
journal, November 2005

  • Bild, Andrea H.; Yao, Guang; Chang, Jeffrey T.
  • Nature, Vol. 439, Issue 7074
  • DOI: 10.1038/nature04296

Diversity of gene expression in adenocarcinoma of the lung
journal, November 2001

  • Garber, M. E.; Troyanskaya, O. G.; Schluens, K.
  • Proceedings of the National Academy of Sciences, Vol. 98, Issue 24
  • DOI: 10.1073/pnas.241500798

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
journal, March 2014


ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
journal, January 2013

  • Sholl, Lynette M.; Sun, Heather; Butaney, Mohit
  • The American Journal of Surgical Pathology, Vol. 37, Issue 9
  • DOI: 10.1097/PAS.0b013e3182960fa7

Abstract 3764: SC-1, a sorafenib derivative, induces apoptosis in epidermal growth factor receptor wild type non-small cell lung cancer through the inhibition of signal transducers and activators of transcription 3
conference, November 2014

  • Wang, Cheng-Yi; Chao, Ting-Ting; Shiau, Chung-Wai
  • Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, Experimental and Molecular Therapeutics
  • DOI: 10.1158/1538-7445.AM2012-3764

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
journal, February 2014

  • Huang, Qinhua; Johnson, Ted W.; Bailey, Simon
  • Journal of Medicinal Chemistry, Vol. 57, Issue 4
  • DOI: 10.1021/jm401805h

Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types
journal, April 2013


Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
journal, February 2015


The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation
journal, July 2012


Works referencing / citing this record:

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
journal, December 2017


Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
journal, March 2016


The role of HGF/c-MET signaling pathway in lymphoma
journal, December 2016


Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
journal, May 2016


Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
journal, November 2015

  • Shea, Meghan; Costa, Daniel B.; Rangachari, Deepa
  • Therapeutic Advances in Respiratory Disease, Vol. 10, Issue 2
  • DOI: 10.1177/1753465815617871

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
journal, January 2017


Targeted therapies and immunotherapy in non-small-cell lung cancer
journal, June 2016


ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
journal, January 2016


Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC
journal, January 2020


Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
journal, May 2015


TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
journal, July 2017


Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
journal, April 2018

  • Facchinetti, Francesco; Friboulet, Luc
  • Translational Lung Cancer Research, Vol. 7, Issue S2
  • DOI: 10.21037/tlcr.2018.02.04

Anaplastic lymphoma kinase: Role in cancer and therapy perspective
journal, November 2015


Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
journal, July 2017

  • Narayanan, Dilip; Gani, Osman A. B. S. M.; Gruber, Franz X. E.
  • Journal of Cheminformatics, Vol. 9, Issue 1
  • DOI: 10.1186/s13321-017-0229-8

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
journal, September 2018

  • Kato, Yuka; Ninomiya, Kiichiro; Ohashi, Kadoaki
  • Cancer Science, Vol. 109, Issue 10
  • DOI: 10.1111/cas.13752

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
journal, February 2018


Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
journal, March 2019


The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
journal, August 2019


Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
journal, June 2019


Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
journal, June 2017

  • Collier, Thomas Lee; Normandin, Marc D.; Stephenson, Nickeisha A.
  • Nature Communications, Vol. 8, Issue 1
  • DOI: 10.1038/ncomms15761

Current Landscape of Targeted Therapy in Lung Cancer
journal, September 2017

  • Mayekar, Manasi K.; Bivona, Trever G.
  • Clinical Pharmacology & Therapeutics, Vol. 102, Issue 5
  • DOI: 10.1002/cpt.810

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
journal, July 2017

  • Rossi, Giulio; Jocollé, Genny; Conti, Antonia
  • Lung Cancer: Targets and Therapy, Vol. Volume 8
  • DOI: 10.2147/lctt.s120172

Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma
journal, December 2015


Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments: A MD Simulation and NMR Study
journal, December 2019


The role of HGF/c-MET signaling pathway in lymphoma
journal, December 2016


Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
journal, September 2018

  • Kato, Yuka; Ninomiya, Kiichiro; Ohashi, Kadoaki
  • Cancer Science, Vol. 109, Issue 10
  • DOI: 10.1111/cas.13752

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
journal, August 2017

  • Schram, Alison M.; Chang, Matthew T.; Jonsson, Philip
  • Nature Reviews Clinical Oncology, Vol. 14, Issue 12
  • DOI: 10.1038/nrclinonc.2017.127

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
journal, August 2019